<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040898</url>
  </required_header>
  <id_info>
    <org_study_id>01-002</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-01002</secondary_id>
    <secondary_id>NCI-G02-2084</secondary_id>
    <nct_id>NCT00040898</nct_id>
  </id_info>
  <brief_title>Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed</brief_title>
  <official_title>Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the&#xD;
      growth of tumor cells and stimulate a person's immune system to help kill tumor cells. This&#xD;
      may be an effective treatment following hepatic artery embolization.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of Sho-saiko-to following hepatic artery&#xD;
      embolization in treating patients who have liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival of patients with unresectable hepatocellular carcinoma&#xD;
           treated with Sho-saiko-to after ablation therapy with embolization vs historical control&#xD;
           patients.&#xD;
&#xD;
        -  Compare the liver function and alpha fetoprotein levels in patients treated with this&#xD;
           drug vs historical control patients.&#xD;
&#xD;
        -  Compare the intervention-free survival in patients treated with this drug vs historical&#xD;
           control patients.&#xD;
&#xD;
      OUTLINE: Beginning within 1 week after the first course of ablation therapy with&#xD;
      embolization, patients receive oral Sho-saiko-to three times daily. Treatment with&#xD;
      Sho-saiko-to continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study within 18-24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sho-saiko-to</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following conditions:&#xD;
&#xD;
               -  Histologically confirmed unresectable hepatocellular carcinoma&#xD;
&#xD;
               -  Serum alpha-fetoprotein (AFP) level greater than 500 ng/mL with cirrhosis&#xD;
&#xD;
               -  Serum AFP level greater than 500 ng/mL with a liver mass and positive hepatitis B&#xD;
                  or C serology&#xD;
&#xD;
          -  Receiving ablation therapy with embolization&#xD;
&#xD;
          -  Extrahepatic disease allowed&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT less than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT or INR less than 1.6 times ULN (if not receiving warfarin for anticoagulation)&#xD;
&#xD;
          -  Albumin greater than 2.5 g/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.8 mg/dL&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 50% predicted OR&#xD;
&#xD;
          -  DLCO at least 70% predicted if total lung capacity less than 80% predicted&#xD;
&#xD;
          -  No significant lung disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled infection or pain&#xD;
&#xD;
          -  No other condition that would significantly impair cognitive functioning during the&#xD;
             study&#xD;
&#xD;
          -  No overt psychosis, mental disability, or other incompetency that would preclude study&#xD;
&#xD;
          -  No other life-threatening illness for which the prognosis is poorer than for&#xD;
             hepatocellular carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent interferon&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy within 4 weeks of initiating ablation therapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy within 4 weeks of initiating ablation therapy&#xD;
&#xD;
          -  Concurrent radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior ablation therapy&#xD;
&#xD;
          -  No other concurrent Sho-saiko-to or any of its constituent plants&#xD;
&#xD;
          -  No other concurrent anticancer medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald DeMatteo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

